PAR-22-218: Biology of Bladder Cancer (R01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 12, 2024.
From the official notice on Grants.gov, last changed December 11, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$514,582
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under PAR-22-218 were run by National Cancer Institute (NCI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-218 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-129 | November 19, 2024 | Closed September 7, 2025 | Closed |
Key dates
| Posted | July 26, 2022 |
|---|---|
| Deadline | December 12, 2024 |
| Archived by Grants.gov | January 11, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (68% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Funded under PAR-22-218 so far
NIH funded 6 projects under PAR-22-218 in fiscal 2023 to 2026, at 5 institutions. The median yearly award was $514,582.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Novel mechanism of chemokine nitration in bladder cancer | University of Texas HLTH Science Center | 2026 | $389,933 |
| Investigating mechanisms of tumor plasticity in human bladder cancer | Columbia University Health Sciences | 2026 | $1.4 million |
| Targeting APOBEC3-induced squamous differentiation in bladder cancer | Univ of North Carolina Chapel Hill | 2026 | $514,582 |
| Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | Dana-Farber Cancer Inst | 2026 | $487,506 |
| Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis | Icahn School of Medicine at Mount Sinai | 2026 | $683,333 |
| Investigating mechanisms of bladder cancer metastasis | Columbia University Health Sciences | 2026 | $516,846 |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-218 still open?
No. It closed on December 12, 2024.
Who can apply for Biology of Bladder Cancer (R01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Biology of Bladder Cancer (R01 Clinical Trial Optional)?
Closed December 12, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-218?
NIH RePORTER lists 6 projects funded under PAR-22-218 in fiscal 2023 to 2026, at 5 institutions. The most were at Columbia University Health Sciences, University of Texas HLTH Science Center, Univ of North Carolina Chapel Hill.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)